Brastianos Priscilla K, Kim Albert E, Wang Nancy, Lee Eudocia Q, Ligibel Jennifer, Cohen Justine V, Chukwueke Ugonma N, Mahar Maura, Oh Kevin, White Michael D, Shih Helen A, Forst Deborah, Gainor Justin F, Heist Rebecca S, Gerstner Elizabeth R, Batchelor Tracy T, Lawrence Donald, Ryan David P, Iafrate A John, Giobbie-Hurder Anita, Santagata Sandro, Carter Scott L, Cahill Daniel P, Sullivan Ryan J
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Nat Cancer. 2021 May;2(5):498-502. doi: 10.1038/s43018-021-00198-5. Epub 2021 Apr 8.
Recent studies suggest that the cyclin-dependent kinase (CDK) pathway may be a therapeutic target for brain metastases (BM). Here, we present interim analysis of a basket trial evaluating the intracranial efficacy of the CDK inhibitor palbociclib in patients with progressive BM and CDK alterations. Our study met its primary endpoint and provides evidence for performing molecular testing of archival BM tissue, if available, to inform the choice of CNS-penetrant targeted therapy.
近期研究表明，细胞周期蛋白依赖性激酶（CDK）通路可能是脑转移瘤（BM）的一个治疗靶点。在此，我们展示了一项篮子试验的中期分析，该试验评估了CDK抑制剂哌柏西利对进展性脑转移瘤且有CDK改变患者的颅内疗效。我们的研究达到了主要终点，并为在有存档脑转移瘤组织（若有）时进行分子检测以指导选择具有中枢神经系统穿透性的靶向治疗提供了证据。
